Biblio

Export 6 results:
Author Title [ Type(Desc)] Year
Filters: Keyword is Alzheimer Disease and Author is Blennow, Kaj  [Clear All Filters]
Journal Article
B. Dubois, Feldman, H. H., Jacova, C., Hampel, H., Molinuevo, J. Luis, Blennow, K., DeKosky, S. T., Gauthier, S., Selkoe, D., Bateman, R., Cappa, S., Crutch, S., Engelborghs, S., Frisoni, G. B., Fox, N. C., Galasko, D., Habert, M. - O., Jicha, G. A., Nordberg, A., Pasquier, F., Rabinovici, G., Robert, P., Rowe, C., Salloway, S., Sarazin, M., Epelbaum, S., de Souza, L. C., Vellas, B., Visser, P. J., Schneider, L., Stern, Y., Scheltens, P., and Cummings, J. L., Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria., Lancet Neurol, vol. 13, no. 6, pp. 614-29, 2014.
P. Buchhave, Minthon, L., Zetterberg, H., Wallin, A. K., Blennow, K., and Hansson, O., Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia., Arch Gen Psychiatry, vol. 69, no. 1, pp. 98-106, 2012.
K. E. Melah, Lu, S. Yuan- Fu, Hoscheidt, S. M., Alexander, A. L., Adluru, N., Destiche, D. J., Carlsson, C. M., Zetterberg, H., Blennow, K., Okonkwo, O. C., Gleason, C. E., N Dowling, M., Bratzke, L. C., Rowley, H. A., Sager, M. A., Asthana, S., Johnson, S. C., and Bendlin, B. B., Cerebrospinal Fluid Markers of Alzheimer's Disease Pathology and Microglial Activation are Associated with Altered White Matter Microstructure in Asymptomatic Adults at Risk for Alzheimer's Disease., J Alzheimers Dis, vol. 50, no. 3, pp. 873-86, 2016.
J. Spiegel, Pirraglia, E., Osorio, R. S., Glodzik, L., Li, Y., Tsui, W., Louis, L. A. Saint, Randall, C., Butler, T., Xu, J., Zinkowski, R. P., Zetterberg, H., Fortea, J., Fossati, S., Wisniewski, T., Davies, P., Blennow, K., and de Leon, M. J., Greater specificity for cerebrospinal fluid P-tau231 over P-tau181 in the differentiation of healthy controls from Alzheimer's disease., J Alzheimers Dis, vol. 49, no. 1, pp. 93-100, 2016.
K. Blennow and Zetterberg, H., The Past and the Future of Alzheimer's Disease Fluid Biomarkers., J Alzheimers Dis, vol. 62, no. 3, pp. 1125-1140, 2018.
S. Salloway, Sperling, R., Fox, N. C., Blennow, K., Klunk, W., Raskind, M., Sabbagh, M., Honig, L. S., Porsteinsson, A. P., Ferris, S., Reichert, M., Ketter, N., Nejadnik, B., Guenzler, V., Miloslavsky, M., Wang, D., Lu, Y., Lull, J., Tudor, I. Cristina, Liu, E., Grundman, M., Yuen, E., Black, R., and H Brashear, R., Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease., N Engl J Med, vol. 370, no. 4, pp. 322-33, 2014.